Last Updated on December 31, 2023 by The Health Master
The Drug Technical Advisory Board (DTAB) recently recommended to the Drugs Controller General of India (DCGI) an amendment in provisions of the New Drugs and Clinical Trials Rules, 2019 for granting license to manufacture and stock new drugs and vaccines, under clinical trial, for sale or distribution, official sources said yesterday.
DTAB, however, said such drugs should be marketed, sold and distributed only after clearance of clinical trial results.
Based on the recommendation, DCGI has sent a draft proposal to the union health ministry for approval, the sources said.
According to an official source, the DCGI mentioned in the draft proposal, “DTAB has recommended that the proposed provisions for grant of license to manufacture and stock of new drug which is under clinical trial is considered appropriate for drugs/vaccines being developed for emergency / life-saving / C-19 and similar such conditions of public health importance.
However, such drugs should be marketed, sold and distributed only after clearance of clinical trial results.” Accordingly, a draft notification has been prepared and forwarded to the ministry, the official source said.
Prakash Kumar Singh, Director, Government and Regulatory Affairs, Serum Institute of India, had last year written to union health minister Mansukh Mandaviya for reforms in the drug regulatory systems, the source said.
In his letter, Singh stated that the health ministry had issued a gazette notification dated 18th May, 2020 to manufacture and stock C-19 vaccine which is under clinical trial for marketing authorization for sale or distribution.
“Because of this rule, it became possible for us to manufacture and stockpile the C-19 vaccine during clinical trials, and we could make available the C-19 vaccine in such a short span of time period to protect millions of lives.
It will be a big help for vaccine industry if this rule is implemented for non-C-19 vaccines also,” Singh had stated.
“This will also be in line with our prime minister’s vision of ‘ease of doing business’ in India and will further encourage his dream project ‘Making in India for the world’,” Singh had mentioned in his letter, according to the official source.
Various industry experts and subject experts are of opinion that if the government approves the recommendations of DTAB and DCGI, it will be a revolutionary change in drug rules in the public interest.
This new provision will save the manufacturer substantial time in producing and launching vaccines in the market and will give a boost to the efforts being made by the government to make India a pharmaceutical hub of the world.
Notifications: New Drugs, FDC, Clinical Trial
Other details about New Drugs, FDCs, Clinical trial
Four-side seal pouch machine introduced for Pharma Companies
Dr Reddy’s Laboratories launches generic Vasopressin injection USP
Biological E seeks extension from DCGI for its vaccine shelf life
USFDA gives nod to Lupin for Arformoterol Tartrate inhalation solution
Drug recall: Red Pill Capsules recalled due to this reason
Manufacturers of these 11 drugs to incorporate newly identified ADRs in packing
Govt releases new National List of Essential AYUSH Medicines: Download
Illegal Pharmaceutical unit unearthed by FDA, Police
First Nasal Spray for covid-19 treatment in India: 10 things to know
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
